ZNF623

Across TCGA pan-cancer cohorts, ZNF623 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF623 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF623 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF623 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and UCEC are the cancer types where ZNF623 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.334	0.916	<.001	62	view →
GBM	DFS	Quartile	All	0.847	0.517	.019	9	view →
UCEC	DFS	Quartile	All	0.632	1.000	.044	8	view →
LUAD	DFS	Median	All	0.480	0.779	.023	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF623–PDAC (DFS)

Open the PDAC breakdown →